Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Novartis' Transderm Scop

This article was originally published in The Tan Sheet

Executive Summary

Novartis' Transderm Scop: Rx scopolamine motion sickness transdermal patch being reintroduced through direct-mail campaigns to health care professionals in September and consumers in November. Transderm Scop originally was marketed as an OTC product. In an attempt to position Transderm Scop against available OTC motion sickness alternatives such as Pharmacia & Upjohn's Dramamine, Novartis is relying on lower pricing and insurance coverage of the Rx product. The scopolamine 1.5 mg patch will begin shipping Oct. 1 and reach pharmacy shelves in mid-November. The product was withdrawn from the market in August 1994 due to manufacturing problems. Novartis received FDA approval to modify the manufacturing process in October. The brand is being remarketed under the company's Consumer Health division...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel